Skip to content

Study · Observational study · n = 30 · 2025

6 results

Evaluation of gastric content in fasting patient during semaglutide use: an observational study.

Queiroz VNF, Falsarella PM, Chaves RCF, Francisco Neto MJ, Silva JM Jr, Araújo GF, Takaoka F, Pfeilsticker FJDA, Mendes GF, Garcia RG

Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery10 Sept 2024Cited by 6 (Europe PMC)

PMID39343660 (opens in a new tab)DOI10.1016/j.soard.2024.08.039 (opens in a new tab)PepBankPUB-39343660
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanObservational studyOther

    In fasting adult volunteers, a full stomach was more common with recent semaglutide use than in controls (73% vs 7%).

    In plain wordsIn fasting adults, a full stomach was more common in people who had used semaglutide than in people who had not.

    Peptide
    Semaglutide
    Outcome
    IncreaseFull stomach on gastric ultrasound
    Study

    n = 30

    Comparator
    Volunteers who never used semaglutide
    Analysis
    Primary
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Full stomach, semaglutide
    73%
    11 of 15
    Full stomach, control
    7%
    1 of 15

    Source sentences

    Summary
    The semaglutide group exhibited a higher prevalence of full stomach (11 of 15 [73%] versus 1 of 15 [7%], P < .001; adjusted to age P = .003).
    2 context sentences
    Summary · context
    We included 30 consecutive volunteers aged ≥18 years who had undergone a minimum fasting period of 8 hours for solid foods and 2 hours for clear, residue-free liquids.
    Summary · context
    The intervention group consisted of 15 volunteers who had used semaglutide within the last 7 days, whereas the control group consisted of 15 volunteers who had never used semaglutide.
  2. 02HumanObservational studySafety outcome

    In fasting adult volunteers, early satiety was more common with recent semaglutide use than in controls (67% vs 0%).

    In plain wordsEarly feeling of fullness was more common in people who had used semaglutide than in people who had not.

    Peptide
    Semaglutide
    Outcome
    IncreaseEarly satiety
    Study

    n = 30

    Comparator
    Volunteers who never used semaglutide
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Early satiety, semaglutide
    67%
    10 of 15
    Early satiety, control
    0%
    0 of 15

    Source sentences

    Summary
    The semaglutide group also exhibited a higher prevalence of early satiety (10 of 15 [67%] versus 0 of 15 [0%], P < .001), loss of appetite (10 of 15 [67%] versus 0 of 15 [0%], P < .001), gastric fullness (8 of 15 [53%] versus 0 of 15 [0%], P = .002), and nausea (7 of 15 [47%] versus 1 of 15 [7%], P = .035).
    2 context sentences
    Summary · context
    We included 30 consecutive volunteers aged ≥18 years who had undergone a minimum fasting period of 8 hours for solid foods and 2 hours for clear, residue-free liquids.
    Summary · context
    The intervention group consisted of 15 volunteers who had used semaglutide within the last 7 days, whereas the control group consisted of 15 volunteers who had never used semaglutide.
  3. 03HumanObservational studySafety outcome

    In fasting adult volunteers, loss of appetite was more common with recent semaglutide use than in controls (67% vs 0%).

    In plain wordsLoss of appetite was more common in people who had used semaglutide than in people who had not.

    Peptide
    Semaglutide
    Outcome
    IncreaseLoss of appetite
    Study

    n = 30

    Comparator
    Volunteers who never used semaglutide
    Outcome group
    Appetite and food intake · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Loss of appetite, semaglutide
    67%
    10 of 15
    Loss of appetite, control
    0%
    0 of 15

    Source sentences

    Summary
    The semaglutide group also exhibited a higher prevalence of early satiety (10 of 15 [67%] versus 0 of 15 [0%], P < .001), loss of appetite (10 of 15 [67%] versus 0 of 15 [0%], P < .001), gastric fullness (8 of 15 [53%] versus 0 of 15 [0%], P = .002), and nausea (7 of 15 [47%] versus 1 of 15 [7%], P = .035).
    2 context sentences
    Summary · context
    We included 30 consecutive volunteers aged ≥18 years who had undergone a minimum fasting period of 8 hours for solid foods and 2 hours for clear, residue-free liquids.
    Summary · context
    The intervention group consisted of 15 volunteers who had used semaglutide within the last 7 days, whereas the control group consisted of 15 volunteers who had never used semaglutide.
  4. 04HumanObservational studySafety outcome

    In fasting adult volunteers, gastric fullness was more common with recent semaglutide use than in controls (53% vs 0%).

    In plain wordsA feeling of stomach fullness was more common in people who had used semaglutide than in people who had not.

    Peptide
    Semaglutide
    Outcome
    IncreaseGastric fullness
    Study

    n = 30

    Comparator
    Volunteers who never used semaglutide
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Gastric fullness, semaglutide
    53%
    8 of 15
    Gastric fullness, control
    0%
    0 of 15

    Source sentences

    Summary
    The semaglutide group also exhibited a higher prevalence of early satiety (10 of 15 [67%] versus 0 of 15 [0%], P < .001), loss of appetite (10 of 15 [67%] versus 0 of 15 [0%], P < .001), gastric fullness (8 of 15 [53%] versus 0 of 15 [0%], P = .002), and nausea (7 of 15 [47%] versus 1 of 15 [7%], P = .035).
    2 context sentences
    Summary · context
    We included 30 consecutive volunteers aged ≥18 years who had undergone a minimum fasting period of 8 hours for solid foods and 2 hours for clear, residue-free liquids.
    Summary · context
    The intervention group consisted of 15 volunteers who had used semaglutide within the last 7 days, whereas the control group consisted of 15 volunteers who had never used semaglutide.
  5. 05HumanObservational studySafety outcome

    In fasting adult volunteers, nausea was more common with recent semaglutide use than in controls (47% vs 7%).

    In plain wordsNausea was more common in people who had used semaglutide than in people who had not.

    Peptide
    Semaglutide
    Outcome
    IncreaseNausea
    Study

    n = 30

    Comparator
    Volunteers who never used semaglutide
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Nausea, semaglutide
    47%
    7 of 15
    Nausea, control
    7%
    1 of 15

    Source sentences

    Summary
    The semaglutide group also exhibited a higher prevalence of early satiety (10 of 15 [67%] versus 0 of 15 [0%], P < .001), loss of appetite (10 of 15 [67%] versus 0 of 15 [0%], P < .001), gastric fullness (8 of 15 [53%] versus 0 of 15 [0%], P = .002), and nausea (7 of 15 [47%] versus 1 of 15 [7%], P = .035).
    2 context sentences
    Summary · context
    We included 30 consecutive volunteers aged ≥18 years who had undergone a minimum fasting period of 8 hours for solid foods and 2 hours for clear, residue-free liquids.
    Summary · context
    The intervention group consisted of 15 volunteers who had used semaglutide within the last 7 days, whereas the control group consisted of 15 volunteers who had never used semaglutide.
  6. 06HumanObservational studyOther

    In the semaglutide group, no volunteer had a stomach without gastric contents.

    In plain wordsIn the semaglutide group, no volunteer had a completely empty stomach on ultrasound.

    Peptide
    Semaglutide
    Outcome
    DecreaseEmpty stomach on gastric ultrasound
    Study

    n = 30

    Comparator
    Volunteers who never used semaglutide
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Additionally, there is no case in the semaglutide group with no gastric contents.
    2 context sentences
    Summary · context
    We included 30 consecutive volunteers aged ≥18 years who had undergone a minimum fasting period of 8 hours for solid foods and 2 hours for clear, residue-free liquids.
    Summary · context
    The intervention group consisted of 15 volunteers who had used semaglutide within the last 7 days, whereas the control group consisted of 15 volunteers who had never used semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.